A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

Cancer Chemother Pharmacol. 2002 Aug;50(2):151-4. doi: 10.1007/s00280-002-0470-2. Epub 2002 Jul 5.

Abstract

Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.

Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m(2) was given to the first 11 patients and was reduced to 560 mg/m(2) for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients.

Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia.

Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acridines / administration & dosage
  • Acridines / adverse effects
  • Acridines / therapeutic use*
  • Adult
  • Aged
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Drug Administration Schedule
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Infusions, Intravenous
  • Intercalating Agents / administration & dosage
  • Intercalating Agents / adverse effects
  • Intercalating Agents / therapeutic use
  • Middle Aged
  • Neutropenia / chemically induced
  • Nucleic Acid Synthesis Inhibitors / administration & dosage
  • Nucleic Acid Synthesis Inhibitors / adverse effects
  • Nucleic Acid Synthesis Inhibitors / therapeutic use
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Remission Induction
  • Salvage Therapy
  • Treatment Outcome
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / pathology
  • Vomiting / chemically induced

Substances

  • Acridines
  • Enzyme Inhibitors
  • Intercalating Agents
  • Nucleic Acid Synthesis Inhibitors
  • Pyrazoles
  • NSC 366140